Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6667348 | 0.99 | TACR2 (0.69) | TACR2 | |
| Hydrochloric Acid SCHEMBL6667347 | 0.99 | TACR2 (0.69) | TACR2 | |
| SCHEMBL8438798 | 0.95 | TACR2 (0.72) | TACR2 | |
| SCHEMBL8438796 | 0.95 | TACR2 (0.72) | TACR2 | |
| Hydrochloric Acid SCHEMBL7046417 | 0.95 | TACR2 (0.71) | TACR2 | |
| Hydrochloric Acid SCHEMBL7046414 | 0.95 | TACR2 (0.71) | TACR2 | |
| SCHEMBL29395251 | 0.92 | TACR2 (0.72) | TACR2 | |
| SCHEMBL1387904 | 0.92 | TACR2 (0.72) | TACR2 | |
| SCHEMBL1387902 | 0.92 | TACR2 (0.72) | TACR2 | |
| Hydrochloric Acid SCHEMBL5813499 | 0.92 | TACR2 (0.71) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2005-09-15 | — | — | US | claimed |
| EP-1444220-A1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | claimed |
| WO-2003037889-A1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | claimed |
| US-7368461-B2 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | TACR1, TACR2, BDKRB1 | TACR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.